Advertisement Cancer Therapeutics Plans To Acquire 25% Stake In Nanotherapies - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cancer Therapeutics Plans To Acquire 25% Stake In Nanotherapies

Cancer Therapeutics, a biotechnology business incubator focused on disruptive cancer treatments and nanotechnology, has revealed its plan to sign a definitive agreement to purchase a 25% stake in NanoTherapies.

The agreement will be finalized by the end of May 2009.

NanoTherapies is engaged in the development of life-changing therapies for cancer treatment based on an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications.

Utah-based Cancer Therapeutics seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at cancer.